Establishment Labs Reports 33.9% Revenue Growth and First Positive Quarterly Free Cash Flow
Establishment Labs reported Q3 2026 revenue of $72.0M, up 33.9% YoY, with a net loss of $10.7M. Adjusted EBITDA was $6.4M, and free cash flow was $5.1M, the first positive quarter. The company raised its 2026 revenue outlook to over $274M. U.S. revenue rose 119.0%, and international revenue increased 9.7%.
How this was made
The 30-second read
Why it matters
Key decision inputs for traders are the raised 2026 revenue outlook, the first positive quarterly free cash flow, and FDA approval of additional Motiva implant sizes, which together can shift expectations for growth and cash generation.
Market read
A quantified earnings and guidance update with multiple positive cash-flow and regulatory/product catalysts, likely affecting near-term positioning in the name.
What to watch
Gross margin improved but included restructuring-related inventory charges; traders may scrutinize whether the adjusted gross margin and free cash flow are repeatable in upcoming quarters, especially with manufacturing scaling.
Background
The article summarizes Establishment Labs Holdings’ Q3 2026 financial results, cash flow, and updated 2026 revenue outlook, alongside product and manufacturing updates.
Ticker impact
Establishment Labs reported Q3 2026 revenue of $72.0M (+33.9% YoY) and raised its 2026 revenue outlook to more than $274M.
Likely upward bias as the market reprices growth and cash-flow trajectory after the raised 2026 revenue outlook.
This is a company-specific earnings and guidance update with multiple quantified positives (revenue growth, first positive FCF quarter, outlook raise), which typically drives near-term repricing even if profitability remains negative.
Market effects
Supports the broader minimally invasive aesthetic/implant medtech narrative by signaling demand expansion and improving cash generation.
U.S. commercial footprint growth and FDA-related implant size approval may reinforce U.S. medtech demand expectations.
Limited direct global read-through beyond implant platform adoption and manufacturing capacity expansion.
Counterpoint
Despite revenue growth and first positive free cash flow, the company still reported a net loss and an operating loss, so the market may focus on sustainability of margins and cash conversion.
Key entities
- companyEstablishment Labs Holdings Inc.
Reported Q3 2026 revenue growth, first positive quarterly free cash flow, and raised 2026 revenue outlook; also cited FDA approval and a new NuSil supply agreement.
- supplierNuSil
Announced as a new supply agreement partner to support long-term manufacturing capacity.
- regulatorFDA
Approved additional smaller Motiva implant sizes for the U.S. market.
